Catalytic Enantioselective Cyclopropylalkynylation of Aldimines Generated In Situ from α-Amido Sulfones

Alicia Monleón, Gonzalo Blay * and José R. Pedro *

Departament de Química Orgànica, Facultad de Química, Universitat de València, C/Dr. Moliner 50, 46100 Burjassot, Spain; alicia.monleon@uv.es
* Correspondence: gonzalo.blay@uv.es (G.B.); jose.r.pedro@uv.es (J.R.P.)

Abstract: A convenient procedure of synthesis of N-carbamoyl-protected propargylic amines substituted with a cyclopropyl group from α-amido sulfones and cyclopropylacetylene is described. The reaction is catalyzed by a chiral BINOL-type zinc complex and provides the corresponding products in good yields and enantioselectivities.

Keywords: N-carbamoyl-protected propargylic amines; α-amido sulfones; cyclopropylacetylene; BINOL; zinc complex

1. Introduction

Propargylic amines are an important class of alkyne-coupled nitrogen compounds used as building blocks for the synthesis of biologically active compounds of interest in the pharmaceutical and agrochemical industries [1–3]. Recently, their application in the chemical fixation of carbon dioxide has been also described [4–6]. Consequently, a number of methodologies detailing the preparation of these building blocks have been disclosed, mostly involving the direct addition of alkynyl nucleophiles to imines [7–12].

On the other hand, the presence of the cyclopropyl group in organic compounds has attracted enormous attention due to its exceptional steric, electronic, and conformational properties as a consequence of its tensioned structure [13–15]. Its presence in nature (terpenes, antibiotics, pheromones, or fatty acids) has led to the search for new biologically active compounds incorporating this ring. In fact, several drugs with antitumor, anti-inflammatory, or antimalarial activity, among others, have been developed [16]. In some cases, such as Efavirenz (Sustiva®, Bristol Myers Squibb), the cyclopropylacetylene group is present in its structure [17–21].

The catalytic enantioselective addition of cyclopropylacetylene to the C=N bond of imines would allow the cyclopropyl group to be easily introduced as a substituent in a propargylic amine. However, despite extensive studies on the catalytic asymmetric alkyynylation of imines, only one example of enantioselective cyclopropylalkynylation reaction using a stoichiometric amount of a chiral ligand has been described by Jiang and Si (Scheme 1a) [22]. In particular, this procedure involves the enantioselective cyclopropylalkynylation of a cyclic N-acyl ketimine using 1.1 equivalents of a chloramphenicol-derived chiral ligand and zinc triflate in the presence of 2.5 equivalents of triethylamine. This procedure allowed them to synthesize DPC-961, a second-generation non-nucleoside HIV reverse transcriptase inhibitor analogous to Efavirenz.
Molecules 2022, 27, x 2 of 9

are relatively unstable. However, by using the corresponding α-amido sulfones, it is possible to prepare these imines in situ to avoid their synthesis and isolation, thus circumventing their instability (Scheme 1b) [24–26].

In this kind of reaction, the substituent on the nitrogen atom of the imine plays a crucial role, thus strongly affecting the electrophilicity of the imine. Moreover, the synthetic utility of this reaction also depends on the ease of elimination of this substituent in the resulting amines. The tert-butoxycarbonyl (BOC) and benzyloxycarbonyl (Cbz) protecting groups fulfill these requirements, but the corresponding NBOc and NCbz imines are relatively unstable. However, by using the corresponding α-amido sulfones, it is possible to prepare these imines in situ to avoid their synthesis and isolation, thus circumventing their instability (Scheme 1b) [24–26].

In this paper, we describe the enantioselective cyclopropylalkynylation of aldimes generated in situ from α-amido sulfones, catalyzed by a chiral BINOL-type zinc complex, as a convenient procedure of synthesis of N-carbamoyl-protected propargylic amines substituted with a cyclopropyl group (Scheme 1c).

2. Results and Discussion

Having in mind the importance of α-amido sulfones as a convenient starting material of imine, we carried out the preparation of a set of 15 α-amido sulfones 1 from the corresponding aldehydes, following the method described by Engberts [27].

Starting from amido sulfone 1a, we conducted the addition of cyclopropylacetylene 2 under the same conditions used by our group in the addition of phenylacetylene and other arylacetylens to different α-amido sulfones [23]. Thus, a 1 M Et2Zn solution in hexanes (3 eq.) was added dropwise to a mixture of chiral BINOL-type ligand L (0.2 eq.) and cyclopropylacetylene (7.2 eq.) in CH2Cl2 at room temperature. After stirring for 2 h, the reaction mixture was cooled to 0 °C and then a solution of the α-amido sulfone 1a (1 eq.) in CH2Cl2 was added. Under these reaction conditions the corresponding propargylic Cbz-amide 3a was obtained with good yield (72%) and enantiomeric excess (86% e.e.)

These reaction conditions were used for the addition of cyclopropylacetylene 2 to several N-benzyloxycarbonyl-para-toluenesulfones 1 derived from substituted benzaldehydes with good results (Scheme 2). Both electron-donating (Me) and electron-withdrawing (F, Cl, Br) substituents in para, meta, and ortho positions were well tolerated, providing the expected products with good yields and enantioselectivities ranging from 89 to 96% ee. It is interesting to remark on the results obtained with the ortho-amido sulfones derived from ortho-substituted benzaldehydes. In the case of the ortho-methyl derivative, the reaction

Scheme 1. Enantioselective alkynylation of ketimines and α-amido sulfones. (a) Enantioselective cyclopropylalkynylation of trifluoromethylketimines [22]. (b) Enantioselective alkynylation of α-amido sulfones [23]. (c) Enantioselective cyclopropylalkynylation of α-amido sulfones.

Previous work

![Previous work diagram]

This work

![This work diagram]
product was obtained with an excellent 96% ee, whereas in the case of the larger ortho-chloro the reaction product was obtained with a 92% e.e., although in this second case the yield was lower (30%). Bulky α-amido sulfone 1i derived from 2-naphthylcarbaldehyde gave the corresponding product 3i with a very good ee value (90%) and acceptable yield (46%).

Scheme 2. Enantioselective addition of cyclopropylacetylene (2) to N-benzyloxycarbonyl-para-toluenesulfones 1. Substrate scope study.
α-Amido sulfones (1j–1l) derived from heteroaromatic aldehydes bearing electron-rich five-membered heterocycles were also suitable substrates. On the other hand, α-amido sulfones derived from 2-furan (1j) and 2-thiophene carbaldehyde (1k) give the reaction products with very good enantiomeric excesses (92% and 84%) and yields (68% and 64%); α-amido sulfone derived from 3-furan carbaldehyde (1l) gives poorer results (69% e.e. and 52% yield). Finally, the aliphatic α-amido sulfones 1m–o reacted with cyclopropylacetylene 2 to give the corresponding propargylic Cbz-amides 3m–o with moderate yields (50–63%) and enantioselectivities (42–65% e.e.). In these cases, substrates bearing a secondary α-alkyl substituent (1o) give better results (63% yield, 65% e.e.) than those derived from linear alkyl aldehydes (1m–n) (50–59% yield, 42–43% e.e.)

The stereochemistry of the newly formed stereogenic center in the resulting products was assigned to be S under the assumption of a uniform mechanistic pathway as that of the reaction of α-amido sulfones with phenylacetylene under the same reaction conditions [23,28].

3. Materials and Methods

3.1. General Information

All reactions were performed under an inert atmosphere of nitrogen in round-bottomed flasks oven-dried overnight at 120 °C. All commercial reagents were used as received without additional purification. Dichloromethane was distilled from CaH₂ and stored over molecular sieves (4 Å). Reactions were monitored by thin-layer chromatography (TLC) analysis using silica gel 60 (F-254 plates). Flash column chromatography was performed using silica gel 60 (0.040–0.063 mm). All new compounds were characterized by NMR spectroscopy (1H and 13C), high-resolution mass spectroscopy (HRMS), and melting point (if solids). NMR spectra were recorded at 300 MHz for 1H and at 75 MHz for 13C NMR. 1H NMR spectra and 13C NMR spectra were internally referenced to CHCl₃ (δ = 7.26 ppm and 77.0 ppm, respectively). Chemical shifts are reported in ppm. The carbon type was determined by DEPT experiments. The following abbreviations are used to indicate the multiplicity in NMR spectra: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br.s, broad signal. The HRMS experiments were performed with a Q-Tof Premier Mass Spectrometer, equipped with an electrospray ionization (ESI) source. The drying gas and also the nebulizing gas was nitrogen. Specific optical rotations were measured with the use of sodium light (D line 589 nm). Chiral HPLC analyses were performed with a chromatograph and a UV diode array detector on chiral stationary phase columns. The abbreviation Rt is used to indicate the retention time of an enantiomer. α-Amido sulfones 1 were prepared from the corresponding aldehyde, carbamate, and sodium para-toluenesulfinate, as described in the literature [27].

3.2. General Procedure for the Enantioselective Cyclopropylalkynylation of Compounds 1

A 1M solution of Et₂Zn in hexane (0.375 mL, 0.375 mmol) was added dropwise at room temperature under nitrogen to a solution of ligand L (17.7 mg, 0.025 mmol) and cyclopropylacetylene 2 (0.9 mmol) in CH₂Cl₂ (0.4 mL). After stirring for 1.5 h, the reaction mixture was cooled to 0 °C. After 15 min, a solution of α-amido sulfone 1 (0.125 mmol) in CH₂Cl₂ (1.0 mL) was added by syringe. The solution was stirred until the reaction was complete (TLC). The reaction mixture was quenched with water (1.0 mL), extracted with CH₂Cl₂ (3 × 15 mL), dried over MgSO₄, and concentrated under reduced pressure. Purification by flash chromatography on silica gel afforded compound 3. (1H-NMR and 13C-NMR and HPLC traces of compounds 3a–o are shown in Supplementary Materials.)

Benzyl (S)-(3-cyclopropyl-1-phenylprop-2-yn-1-yl)carbamate (3a)

Compound 3a was obtained as a white solid with a yield of 72%; m.p. 102–104 °C; [α]D₀ = –3.1 (c 1.01, CHCl₃, 86% ee); enantiomeric excess (86%) was determined by chiral HPLC (Chiralcel OD-H), hexane/PrOH 90:10, 1 mL/min, major enantiomer Rt = 13.4 min, minor enantiomer Rt = 9.5 min; 1H NMR (300 MHz, CDCl₃) δ 7.48 (d, J = 7.1 Hz, 2H), 7.38–7.29 (m, 8H), 5.66 (d, J = 7.9 Hz, 1H), 5.22 (d, J = 6.5 Hz, 1H), 5.16 (d, J = 12.1 Hz,
Molecules 2022, 27, 3763

1H), 5.10 (d, J = 12.4 Hz, 1H), 1.34 (m, 1H), 0.82–0.76 (m, 2H), 0.74–0.68 (m, 2H); 13C NMR (75.5 MHz, CDCl3) δ 155.3 (C), 139.6 (C), 136.2 (C), 128.6 (CH), 128.5 (CH), 128.1 (CH), 127.9 (CH), 126.9 (CH), 88.8 (C), 73.1 (C), 67.0 (CH2), 47.1 (CH), 8.2 (CH2), −0.5 (CH); HRMS (ESI) m/z: [M + H]+, calcld for C20H20NO2 306.1489, found 306.1489.

Benzyl (S)-(3-cyclopropyl-1-(4-tolyl)prop-2-yn-1-yl)carbamate (3b)

Compound 3b was obtained as a white solid with a yield of 58%; m.p. 104–107 °C; [α]D20 = −9.4 (c 1.00, CHCl3, 93% ee); enantiomeric excess (93%) was determined by chiral HPLC (Chiralcel AD-H), hexane/PrOH 90:10, 1 mL/min, major enantiomer Rt = 11.9 min, minor enantiomer Rt = 12.6 min; 1H NMR (300 MHz, CDCl3) δ 7.37–7.29 (m, 7H), 7.15 (d, J = 8.0 Hz, 2H), 5.19–5.13 (m, 2H), 5.09 (d, J = 12.4 Hz, 1H), 2.34 (s, 3H), 1.33–1.24 (m, 1H), 0.81–0.75 (m, 2H), 0.73–0.67 (m, 2H); 13C NMR (75.5 MHz, CDCl3) δ 155.3 (C), 137.7 (C), 136.8 (C), 136.3 (C), 129.2 (CH), 128.5 (CH), 128.1 (CH), 126.8 (CH), 88.6 (C), 73.3 (C), 67.0 (CH2), 46.8 (CH), 21.1 (CH3), 8.2 (CH2), −0.5 (CH); HRMS (ESI) m/z: [M + H]+, calcld for C21H22NO2 320.1645, found 320.1643.

Benzyl (S)-(3-cyclopropyl-1-(4-fluorophenyl)prop-2-yn-1-yl)carbamate (3c)

Compound 3c was obtained as a white solid with a yield of 69%; m.p. 116–117 °C; [α]D20 = −16.6 (c 1.02, CHCl3, 89% ee); enantiomeric excess (89%) was determined by chiral HPLC (Chiralcel AD-H), hexane/PrOH 90:10, 1 mL/min, major enantiomer Rt = 12.8 min, minor enantiomer Rt = 11.5 min; 1H NMR (400 MHz, CDCl3) δ 7.47–7.42 (m, 2H), 7.35–7.31 5.02 (t, J = 8.7 Hz, 2H), 5.63 (d, J = 7.7 Hz, 1H), 5.22 (d, J = 5.4 Hz, 1H), 5.15 (d, J = 12.1 Hz, 1H), 5.09 (d, J = 12.1 Hz, 1H), 1.33–1.24 (m, 1H), 0.82–0.74 (m, 2H), 0.73–0.67 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 162.4 (d, J = 246.5 Hz, C), 155.3 (C), 136.2 (C), 135.6 (d, J = 3.2 Hz, C), 128.7 (d, J = 8.3 Hz, CH), 128.5 (CH), 128.2 (CH), 128.1 (CH), 115.4 (d, J = 21.6 Hz, CH), 89.1 (C), 72.6 (C), 67.1 (CH2), 46.5 (CH), 8.2 (CH2), −0.6 (CH); 19F NMR (282 MHz, CDCl3) δ = −114.9; HRMS (ESI) m/z: [M + H]+, calcld for C20H19FNO2F 324.1394, found 324.1389.

Benzyl (S)-(1-(4-chlorophenyl)-3-cyclopropylprop-2-yn-1-yl)carbamate (3d)

Compound 3d was obtained as a pale yellow solid with a yield of 45%; m.p. 116–117 °C; [α]D20 = −6.3 (c 1.05, CHCl3, 95% ee); enantiomeric excess (95%) was determined by chiral HPLC (Chiralcel AD-H), hexane/PrOH 90:10, 1 mL/min, major enantiomer Rt = 12.5 min, minor enantiomer Rt = 12.0 min; 1H NMR (300 MHz, CDCl3) δ 7.42–7.29 (m, 9H), 5.61 (d, J = 7.9 Hz, 1H), 5.20 (d, J = 6.5 Hz, 1H), 5.15 (d, J = 12.1 Hz, 1H), 5.09 (d, J = 12.8 Hz, 1H), 1.33–1.23 (m, 1H), 0.32–0.24 (m, 2H), 0.72–0.67 (m, 2H); 13C NMR (75.5 MHz, CDCl3) δ 155.3 (C), 138.3 (C), 136.1 (C), 133.7 (C), 128.7 (CH), 128.5 (CH), 128.3 (CH), 128.2 (CH), 128.1 (CH), 89.3 (C), 72.3 (C), 67.2 (CH2), 46.5 (CH), 8.2 (CH2), −0.6 (CH); HRMS (ESI) m/z: [M + H]+, calcld for C20H19NO2Cl 340.1099, found 340.1097.

Benzyl (S)-(1-(4-bromophenyl)-3-cyclopropylprop-2-yn-1-yl)carbamate (3e)

Compound 3e was obtained as a white solid with a yield of 50%; m.p. 131–133 °C; [α]D20 = −3.6 (c 1.06, CHCl3, 92% ee); enantiomeric excess (92%) was determined by chiral HPLC (Chiralcel I-C-H), hexane/PrOH 98:2, 1 mL/min, minor enantiomer Rt = 22.2 min, minor enantiomer Rt = 23.8 min; 1H NMR (300 MHz, CDCl3) δ 7.46 (d, J = 8.5 Hz, 2H), 7.39–7.30 (m, 7H), 5.59 (d, J = 8.3 Hz, 1H), 5.20–5.13 (m, 2H), 0.58 (d, J = 12.1 Hz, 1H), 1.32–1.23 (m, 1H), 0.82–0.74 (m, 2H), 0.72–0.66 (m, 2H); 13C NMR (75.5 MHz, CDCl3) δ 155.2 (C), 138.8 (C), 136.1 (C), 131.6 (CH), 128.6 (CH), 128.5 (CH), 128.2 (CH), 128.1 (CH), 121.9 (C), 89.3 (C), 72.5 (C), 67.2 (CH2), 46.6 (CH), 8.2 (CH2), −0.6 (CH); HRMS (ESI) m/z: [M + H]+, calcld for C20H19NO2Br 384.0594, found 384.0591.

Benzyl (S)-(3-cyclopropyl-1-(3-tolyl)prop-2-yn-1-yl)carbamate (3f)

Compound 3f was obtained as a white solid with a yield of 52%; m.p. 81–83 °C; [α]D20 = −10.6 (c 1.01, CHCl3, 89% ee); enantiomeric excess (89%) was determined by chiral HPLC (Chiralcel OD-H), hexane/PrOH 90:10, 1 mL/min, major enantiomer Rt = 11.1 min, minor enantiomer Rt = 9.3 min; 1H NMR (300 MHz, CDCl3) δ 7.36–7.31 (m, 5H), 7.26–7.21 (m,
Molecules 2022, 27, 3763

3H), 7.11 (d, J = 7.0 Hz, 1H), 5.62 (d, J = 7.8 Hz, 1H), 5.21–5.14 (m, 2H), 5.10 (d, J = 12.4 Hz, 1H), 2.35 (s, 3H), 1.34–1.24 (m, 1H), 0.82–0.75 (2H), 0.74–0.68 (2H). 13C NMR (75.5 MHz, CDCl3) δ 155.3 (C), 139.6 (C), 138.3 (C), 136.3 (C), 128.7 (CH), 128.5 (CH), 128.1 (CH), 127.7 (CH), 123.9 (CH), 88.6 (C), 73.2 (C), 67.0 (CH2), 47.0 (CH), 21.4 (CH3), 8.2 (CH2), −0.5 (CH); HRMS (ESI) m/z: [M + H]+, calcd for C21H22NO2 320.1645, found 320.1642.

Benzyl (R)-(3-cyclopropyl-1-(2-toly)prop-2-yn-1-yl)carbamate (3g)

Compound 3g was obtained as a white solid with a yield of 53%; m.p. 120–122 °C; [α]D20 −24.4 (c 0.98, CHCl3, 96% ee); enantiomeric excess (96%) was determined by chiral HPLC (Chiralcel AD-H), hexane/PrOH 90:10, 1 mL/min, major enantiomer Rt = 11.2 min, minor enantiomer Rt = 13.2 min; 1H NMR (300 MHz, CDCl3) δ 7.54–7.51 (m, 1H), 7.37–7.30 (m, 5H), 7.20 (dd, J = 3.5, 5.6 Hz, 2H), 7.18–7.13 (m, 1H), 5.73 (d, J = 8.2 Hz, 1H), 5.16–5.07 (m, 3H), 2.38 (s, 3H), 1.31–1.22 (m, 1H), 0.80–0.73 (m, 2H), 0.72–0.65 (m, 2H). 13C NMR (75.5 MHz, CDCl3) δ 155.0 (C), 137.4 (C), 136.3 (C), 135.8 (C), 129.5 (CH), 128.5 (CH), 128.12 (CH), 128.06 (CH), 126.7 (CH), 126.2 (CH), 88.3 (C), 73.3 (C), 67.0 (CH2), 44.8 (CH), 19.0 (CH3), 8.2 (CH2), −0.5 (CH); HRMS (ESI) m/z: [M + H]+, calcd for C21H22NO2 320.1645, found 320.1643.

Benzyl (R)-(1-(2-chlorophenyl)-3-cyclopropylprop-2-yn-1-yl)carbamate (3h)

Compound 3h was obtained as a white solid with a yield of 30%; m.p. 110–113 °C; [α]D20 −20.0 (c 0.92, CHCl3, 92% ee); enantiomeric excess (92%) was determined by chiral HPLC (Chiralcel AD-H), hexane/PrOH 90:10, 1 mL/min, major enantiomer Rt = 13.1 min, minor enantiomer Rt = 17.5 min; 1H NMR (300 MHz, CDCl3) δ 7.93 (brs, 1H), 7.84–7.81 (m, 3H), 7.56 (d, J = 8.5 Hz, 1H), 7.39–7.30 (m, 5H), 5.82 (d, J = 8.8 Hz, 1H), 5.14 (d, J = 12.1 Hz, 1H), 5.08 (d, J = 12.4 Hz, 1H), 1.30–1.21 (m, 2H), 0.80–0.73 (m, 2H), 0.72–0.65 (m, 2H). 13C NMR (75.5 MHz, CDCl3) δ 154.9 (C), 136.8 (C), 136.2 (C), 133.1 (C), 130.1 (CH), 129.3 (CH), 128.8 (CH), 128.5 (CH), 128.1 (CH), 127.1 (CH), 88.7 (C), 73.2 (C), 67.0 (CH2), 45.4 (CH), 8.2 (CH2), −0.5 (CH); HRMS (ESI) m/z: [M + H]+, calcd for C20H19NO2Cl 340.1099, found 340.1086.

Benzyl (S)-(3-cyclopropyl-1-(naphthalen-2-yl)prop-2-yn-1-yl)carbamate (3i)

Compound 3i was obtained as a white solid with a yield of 46%; m.p. 106–108 °C; [α]D20 +1.6 (c 0.87, CHCl3, 90% ee); enantiomeric excess (90%) was determined by chiral HPLC (Chiralcel AD-H), hexane/PrOH 90:10, 1 mL/min, major enantiomer Rt = 16.6 min, minor enantiomer Rt = 17.5 min; 1H NMR (300 MHz, CDCl3) δ 7.93 (brs, 1H), 7.84–7.81 (m, 3H), 7.56 (d, J = 8.5 Hz, 1H), 7.39–7.30 (m, 5H), 5.82 (d, J = 8.5 Hz, 1H), 5.31 (d, J = 6.8 Hz, 1H), 5.18 (d, J = 12.1 Hz, 1H), 5.11 (d, J = 12.5 Hz, 1H), 1.37–1.30 (m, 3H), 0.84–0.79 (m, 2H), 0.78–0.71 (m, 2H); 13C NMR (75.5 MHz, CDCl3) δ 155.3 (C), 137.0 (C), 136.2 (C), 133.1 (C), 133.0 (C), 128.5 (CH), 128.2 (CH), 128.1 (CH), 127.6 (CH), 126.3 (CH), 126.2 (CH), 125.6 (CH), 124.9 (CH), 89.1 (C), 73.1 (C), 67.1 (CH2), 47.3 (CH), 8.3 (CH2), −0.5 (CH); HRMS (ESI) m/z: [M + H]+, calcd for C24H18NO3 356.1645, found 356.1645.

Benzyl (R)-(3-cyclopropyl-1-(furan-2-yl)prop-2-yn-1-yl)carbamate (3j)

Compound 3j was obtained as an orange oil with a yield of 68%; [α]D20 +5.9 (c 1.12, CHCl3, 92% ee); enantiomeric excess (92%) was determined by chiral HPLC (Chiralcel AD-H), hexane/PrOH 90:10, 1 mL/min, major enantiomer Rt = 14.4 min, minor enantiomer Rt = 12.7 min; 1H NMR (300 MHz, CDCl3) δ 7.37–7.33 (m, 6H), 6.32–6.31 (m, 2H), 5.69 (d, J = 8.6 Hz, 1H), 5.25 (d, J = 5.4 Hz, 1H), 5.16 (d, J = 12.0 Hz, 1H), 5.10 (d, J = 12.5 Hz, 1H), 1.31–1.22 (m, 1H), 0.81–0.75 (m, 2H), 0.73–0.67 (m, 2H). 13C NMR (75.5 MHz, CDCl3) δ 155.1 (C), 151.6 (C), 142.6 (CH), 136.1 (C), 128.5 (CH), 128.2 (CH), 110.3 (CH), 107.2 (CH), 87.8 (C), 70.9 (C), 67.1 (CH2), 41.3 (CH), 8.2 (CH2), −0.6 (CH); HRMS (ESI) m/z: [M + H]+, calcd for C12H18NO3 296.1281, found 296.1284.

Benzyl (R)-(3-cyclopropyl-1-(thiophen-2-yl)prop-2-yn-1-yl)carbamate (3k)

Compound 3k was obtained as a brown solid with a yield of 64%; m.p. 91–94 °C; [α]D20 −4.8 (c 1.04, CHCl3, 84% ee); enantiomeric excess (84%) was determined by chiral
Molecules 2022, 27, 3763

HPLC (Chiralcel AD-H), hexane/IPrOH 90:10, 1 mL/min, major enantiomer Rt = 14.9 min, minor enantiomer Rt = 12.4 min; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 7.37–7.33 (m, 5H), 7.23 (dd, $J = 5.1, 1.3$ Hz, 1H), 7.12 (dd, $J = 2.7$ Hz, 1H), 6.94 (dd, $J = 5.1, 3.5$ Hz, 1H), 5.86 (d, $J = 8.5$ Hz, 1H), 5.29 (d, $J = 8.1$ Hz, 1H), 5.17 (d, $J = 12.0$ Hz, 1H), 5.11 (d, $J = 12.7$ Hz, 1H), 1.34–1.24 (m, 2H), 2H), 0.83–0.77 (m, 2H), 0.76–0.70 (m, 2H). $^{13}$C NMR (75.5 MHz, CDCl$_3$) $\delta$ 155.1 (C), 143.7 (C), 136.1 (C), 128.5 (CH), 128.2 (CH), 128.1 (CH), 125.7 (CH), 125.5 (CH), 125.3 (CH), 88.3 (C), 72.7 (C), 67.1 (CH), 42.9 (CH), 8.19 (CH$_2$), 8.17 (CH$_2$), −0.6 (CH); HRMS (ESI) $m/z$: [M + H]$^+$, calculated for C$_{18}$H$_{18}$NO$_2$S 312.1053, found 312.1054.

Benzyl (R)-(3-cyclopropyl-1-(furan-3-yl)prop-2-yn-1-yl)carbamate (3I)

Compound 3I was obtained as an orange oil with a yield of 52%; $[^{1}]$$\text{D}_{20}$ = 11.0 (c 1.00, CHCl$_3$, 69% ee); enantiomeric excess (69%) was determined by chiral HPLC (Chiralcel AD-H), hexane/IPrOH 90:10, 1 mL/min, major enantiomer Rt = 13.6 min, minor enantiomer Rt = 11.8 min; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 7.37 (s, 1H), 7.29–7.26 (m, 6H), 6.33 (s, 1H), 5.47 (d, $J = 7.7$ Hz, 1H), 5.10–5.01 (m, 3H), 1.24–1.14 (m, 1H), 0.74–0.68 (m, 2H), 0.63–0.58 (m, 2H). $^{13}$C NMR (75.5 MHz, CDCl$_3$) $\delta$ 155.3 (C), 143.5 (C), 140.2 (CH), 136.2 (C), 128.5 (CH), 128.2 (CH), 128.1 (CH), 125.3 (C), 109.3 (CH), 87.2 (C), 72.6 (C), 67.1 (CH), 39.5 (CH), 8.2 (CH)$_2$, −0.7 (CH); HRMS (ESI) $m/z$: [M + H]$^+$, calculated for C$_{18}$H$_{18}$NO$_2$S 296.1281, found 296.1285.

Benzyl (S)-(1-cyclopropyl-5-phenylpent-1-yn-3-yl)carbamate (3m)

Compound 3m was obtained as a yellow oil with a yield of 59%; $[^{1}]$$\text{D}_{20}$ = 6.6 (c 0.99, CHCl$_3$, 42% ee); enantiomeric excess (42%) was determined by chiral HPLC (Chiralcel AD-H), hexane/IPrOH 90:10, 1 mL/min, major enantiomer Rt = 11.7 min, minor enantiomer Rt = 13.1 min; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 7.37–7.26 (m, 7H), 7.21–7.16 (m, 3H), 5.10 (s, 2H), 4.89 (d, $J = 7.7$ Hz, 1H), 4.46 (q, $J = 7.7$ Hz, 1H), 2.76–2.70 (m, 2H), 2.04–1.87 (m, 2H), 1.29–1.19 (m, 1H), 0.80–0.74 (m, 2H), 0.69–0.63 (2H). $^{13}$C NMR (75.5 MHz, CDCl$_3$) $\delta$ 155.3 (C), 141.1 (C), 136.3 (C), 128.5 (CH), 128.4 (CH), 128.1 (CH), 126.1 (CH), 87.4 (C), 74.0 (C), 66.8 (CH)$_2$, 43.5 (CH), 38.1 (CH)$_2$, 31.9 (CH)$_2$, 8.20 (CH)$_2$, 8.19 (CH)$_2$, −0.7 (CH); HRMS (ESI) $m/z$: [M + H]$^+$, calculated for C$_{22}$H$_{24}$NO$_2$ 334.1802, found 334.1797.

Benzyl (S)-(1-cyclopropylhept-1-yn-3-yl)carbamate (3n)

Compound 3n was obtained as a colorless oil with a yield of 50%; $[^{1}]$$\text{D}_{20}$ = 15.6 (c 1.00, CHCl$_3$, 43% ee); enantiomeric excess (43%) was determined by chiral HPLC (Chiralcel IC), hexane/IPrOH 95:5, 1 mL/min, major enantiomer Rt = 9.6 min, minor enantiomer Rt = 9.2 min; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 7.36–7.31 (m, 5H), 5.10 (s, 2H), 5.84 (d, $J = 5.7$ Hz, 1H), 4.40 (q, $J = 10.5$ Hz, 1H), 1.66–1.55 (m, 2H), 1.40–1.25 (m, 4H), 1.22–1.16 (m, 1H), 0.90 (t, $J = 13.9$ Hz, 3H), 0.77–0.71 (m, 2H), 0.66–0.60 (m, 2H). $^{13}$C NMR (75.5 MHz, CDCl$_3$) $\delta$ 155.3 (C), 136.4 (C), 128.5 (CH), 128.1 (CH), 86.7 (C), 74.6 (C), 66.8 (CH)$_2$, 43.7 (CH), 36.3 (CH)$_2$, 27.7 (CH)$_2$, 22.2 (CH)$_2$, 14.0 (CH$_3$), 8.14 (CH$_2$), 8.13 (CH$_2$), −0.7 (CH); HRMS (ESI) $m/z$: [M + H]$^+$, calculated for C$_{22}$H$_{24}$NO$_2$ 286.1802, found 286.1802.

Benzyl (S)-(1-cyclohexyl-3-cyclopropylprop-2-yn-1-yl)carbamate (3o)

Compound 3o was obtained as a pale yellow solid with a yield of 63%; m.p. 101–104 °C; $[^{1}]$$\text{D}_{20}$ = 23.6 (c 0.90, CHCl$_3$, 65% ee); enantiomeric excess (65%) was determined by chiral HPLC (Chiralcel IC), hexane/IPrOH 98.2, 1 mL/min, major enantiomer Rt = 15.7 min, minor enantiomer Rt = 16.9 min; $^1$H NMR (300 MHz, CDCl$_3$) $\delta$ 7.37–7.34 (m, 5H), 5.12 (d, $J = 12.1$ Hz, 1H), 5.07 (d, $J = 12.1$ Hz, 1H), 4.86 (d, $J = 7.4$ Hz, 1H), 4.29 (d, $J = 7.0$ Hz, 1H), 1.76–1.63 (m, 5H), 1.25–1.03 (m, 7H), 0.77–0.69 (m, 2H), 0.66–0.60 (m, 2H). $^{13}$C NMR (75.5 MHz, CDCl$_3$) $\delta$ 155.5 (C), 136.4 (C), 128.5 (CH), 128.1 (CH), 87.5 (C), 73.2 (C), 66.8 (CH$_2$), 48.8 (CH), 42.9 (CH), 29.2 (CH$_2$), 28.3 (CH$_2$), 26.2 (CH$_2$), 25.9 (CH), 25.8 (CH), 8.2 (CH)$_2$, −0.6 (CH); HRMS (ESI) $m/z$: [M + H]$^+$, calculated for C$_{20}$H$_{26}$NO$_2$ 312.1958, found 312.1959.
4. Conclusions

In summary, we have developed a simple and convenient method for the synthesis of N-carbamoyl-protected propargylic amines substituted with a cyclopropyl group. Although related reactions with α-amido sulfones and phenylacetylene and other arylacetylenes have been reported, this is the first example using cyclopropylacetylene. The reaction is catalyzed by a chiral BINOL-type zinc complex and provides the corresponding products in good yields and enantioselectivities for a number of α-amido sulfones with the best results being obtained with the ortho-methylphenyl derivative.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules27123763/s1, 1H-NMR, 13C-NMR and HPLC traces of compounds 3a-o are available online.

Author Contributions: A.M. performed the experiments; G.B. and J.R.P. designed and supervised the study. A.M., G.B. and J.R.P. wrote the paper. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: We thank the access to the NMR and MS facilities from the Servei Central de Suport a la Investigació Experimental (SCSIE)-UV.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds are not available from the authors.

References and Notes

1. Martinez-Amezaga, M.; Giordano, R.A.; Gori, D.N.P.; Squizatto, C.P.; Giolito, M.V.; Scharovsky, O.G.; Rozados, V.R.; Rico, M.J.; Mata, E.G.; Delpiccolo, C.M.L. Synthesis of propargyamines via the A3 multicomponent reaction and their biological evaluation as potential anticancer agents. Org. Biomol. Chem. 2020, 18, 2475–2486. [CrossRef] [PubMed]

2. Wright, J.L.; Gregory, T.F.; Kesten, S.R.; Boxer, P.A.; Serpa, K.A.; Meltzer, L.T.; Wise, L.D. Subtype-Selective N-Methyl-D-Aspartate Receptor Antagonists: Synthesis and Biological Evaluation of 1-(Heteroarylalkynyl)-4-benzylpiperidines. J. Med. Chem. 2000, 43, 3408–3419. [CrossRef] [PubMed]

3. Kihara, K.; Aoki, T.; Moriguchi, A.; Yamamoto, H.; Maeda, M.; Tojo, N.; Yamanaka, T.; Ohkubo, M.; Matsuoka, N.; Seki, J.; et al. Characterization of the Anti-Platelet Actions of FK419, a Novel Non-Peptide Antagonist of Platelet GPIIb/IIIa. Drug Dev. Res. 2004, 61, 233–241.

4. Rintjema, J.; Kleij, A.W. Substrate-Assisted Carbon Dioxide Activation as a Versatile Approach for Heterocyclic Synthesis. Synthesis 2016, 48, 3863–3878.

5. Dalpozzo, R.; Della Ca’, N.; Gabriele, B.; Mancuso, R. Recent advances in the chemical fixation of carbon dioxide: A green route to carbonylated heterocycle synthesis. Catalysts 2019, 9, 511. [CrossRef]

6. Arshadi, S.; Banaei, A.; Ebrahimiasl, S.; Monfared, A.; Vessally, E. Solvent-free incorporation of CO2 into 2-oxazolidinones: A review. RSC Adv. 2019, 9, 19465–19482. [CrossRef] [PubMed]

7. Blay, G.; Monléon, A.; Pedro, J.R. Recent Developments in Asymmetric Alkynylation of Imines. Curr. Org. Chem. 2009, 13, 1498–1539. [CrossRef]

8. Yoo, W.-J.; Zhao, L.; Li, C.-J. The A3-Coupling (Aldehyde–Alkyne–Amine) Reaction: A Versatile Method for the Preparation of Propargylamines. Aldrichimica Acta 2011, 44, 43–51.

9. Peshkov, V.A.; Pereshivko, O.P.; Van der Eycken, E.V. A walk around the A3-coupling. Chem. Soc. Rev. 2012, 41, 3790–3807. [CrossRef]

10. Bisai, V.; Singh, V.K. Recent developments in asymmetric alkynylation. Tetrahedron Lett. 2016, 57, 4771–4784. [CrossRef]

11. Lauder, K.; Toscani, A.; Scalacci, N.; Castagnolo, D. Synthesis and Reactivity of Propargylamines in Organic Chemistry. Chem. Rev. 2017, 117, 14091–14200. [CrossRef] [PubMed]

12. Ghosh, S.; Biswas, K. Metal-free multicomponent approach for the synthesis of propargylamine: A review. RSC Adv. 2021, 11, 2047–2065. [CrossRef] [PubMed]

13. De Meijere, A.; Kozhushkov, S.I. The Chemistry of Highly Strained Oligospirocyclopropane Systems. Chem. Rev. 2000, 100, 93–142. [CrossRef]
14. De Meijere, A.; Kozhushkov, S.I.; Schill, H. Three-Membered-Ring-Based Molecular Architectures. Chem. Rev. 2006, 106, 4926–4996. [CrossRef] [PubMed]
15. Craig, A.J.; Hawkins, B.C. The Bonding and Reactivity of \( \alpha \)-Carbonyl Cyclopropanes. Synthesis 2020, 52, 27–39. [CrossRef]
16. Časar, Z. Synthetic Approaches to Contemporary Drugs that Contain the Cyclopropyl Moiety. Synthesis 2020, 52, 1315–13452. [CrossRef]
17. Bastos, M.M.P.; Costa, C.C.; Bezerra, T.C.; Da Silva, F.C.; Boechat, N. Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry. Eur. J. Med. Chem. 2016, 108, 455–465. [CrossRef]
18. Zhang, J.; Wang, Y. Synthetic Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) as Anti-HIV Drugs: Efavirenz and its Derivatives. Curr. Org. Chem. 2017, 21, 2196–2206. [CrossRef]
19. Kawai, H.; Kitayama, T.; Tokunaga, E.; Shibata, N. A New Synthetic Approach to Efavirenz through Enantioselective Trifluoromethylation by Using the Ruppert–Prakash Reagent. Eur. J. Org. Chem. 2011, 2011, 5959–5961. [CrossRef]
20. Chinkov, N.; Warm, A.; Carreira, E.M. Asymmetric Autocatalysis Enables an Improved Synthesis of Efavirenz. Angew. Chem. Int. Ed. 2011, 50, 2957–2961. [CrossRef]
21. Griffiths, G.J.; Warm, A. Proposed Mechanism for the Enantioselective Alkynylation of an Aryl Trifluoromethyl Ketone, the Key Step in the Synthesis of Efavirenz. Org. Process. Res. Dev. 2016, 20, 803–813. [CrossRef]
22. Jiang, B.; Si, Y.-G. Highly Enantioselective Construction of a Chiral Tertiary Carbon Center by Alkynylation of a Cyclic N-Acyl Ketimine: An Efficient Preparation of HIV Therapeutics. Angew. Chem. Int. Ed. 2003, 43, 216–218. [CrossRef] [PubMed]
23. Blay, G.; Brines, A.; Monleón, A.; Pedro, J.R. Enantioselective Zinc/BINOL-Catalysed Alkynylation of Aldimines Generated in Situ from \( \alpha \)-Amido Sulfones. Chem. Eur. J. 2012, 18, 2440–2444. [CrossRef]
24. Petrini, M. \( \alpha \)-Amido Sulfones as Stable Precursors of Reactive N-Acylimino Derivatives. Chem. Rev. 2005, 105, 3949–3977. [CrossRef] [PubMed]
25. Alba, A.N.R.; Companyó, X.; Rios, R. Sulfones: New reagents in organocatalysis. Chem. Soc. Rev. 2010, 39, 2018–2033. [CrossRef]
26. Marcantoni, E.; Palmieri, A.; Petrini, M. Recent synthetic applications of \( \alpha \)-amido sulfones as precursors of N-acylimino derivatives. Org. Chem. Front. 2019, 6, 2142–2182. [CrossRef]
27. Engberts, J.B.F.N.; Strating, J. Chemistry of \( \alpha \)-diazosulfones: Part III. A simple preparation of N-(sulfonylmethyl)urethanes by a Mannich condensation. Rec. Trav. Chim. Pays-Bas 1964, 83, 733–736. [CrossRef]
28. In some cases the assigned configuration turned out to be R as a consequence of a change of priorities of the groups attached to the stereogenic carbon atom resulting from the application of the CIP rules.